Adagene Inc. (FRA:978)
3.340
+0.060 (1.83%)
Last updated: Aug 26, 2026, 3:25 PM CET
Adagene Revenue
Adagene had revenue of $1.62M USD in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to $9.29M, up 8,902.38% year-over-year. In the year 2025, Adagene had annual revenue of $7.67M with 7,332.76% growth.
Revenue (ttm)
$9.29M
Revenue Growth
+8,902.38%
P/S Ratio
27.28
Revenue / Employee
$72.58K
Employees
128
Market Cap
221.87M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.76% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 648.90M |
| Novogenia AG | 54.30M |
| Paion AG | 14.81M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 37.15K |
| co.don AG | 22.00K |
| bioXXmed AG | 16.73K |
| 2invest AG | -1.64M |
Adagene News
- 6 days ago - Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Adagene Earnings release: Q2 2026 - Filings
- 14 days ago - Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Adagene Slides: Corporate presentation - Filings
- 3 months ago - Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 3 months ago - Adagene Slides: Investor presentation - Filings
- 3 months ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR - TheFly